In the past week, CLDX stock has gone down by -1.64%, with a monthly decline of -8.21% and a quarterly plunge of -25.17%. The volatility ratio for the week is 7.56%, and the volatility levels for the last 30 days are 6.16% for Celldex Therapeutics Inc The simple moving average for the last 20 days is 0.93% for CLDX stock, with a simple moving average of -28.52% for the last 200 days.
Is It Worth Investing in Celldex Therapeutics Inc (NASDAQ: CLDX) Right Now?
Moreover, the 36-month beta value for CLDX is 1.57. Analysts have varying opinions on the stock, with 9 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CLDX is 64.69M and currently, short sellers hold a 12.74% of that float. On November 21, 2024, CLDX’s average trading volume was 1.10M shares.
CLDX) stock’s latest price update
Celldex Therapeutics Inc (NASDAQ: CLDX) has seen a rise in its stock price by 5.68 in relation to its previous close of 24.98. However, the company has experienced a -1.64% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-20 that HAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 1a study of CDX-622 in healthy volunteers. CDX-622 is a bispecific antibody that targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starvation.
Analysts’ Opinion of CLDX
Many brokerage firms have already submitted their reports for CLDX stocks, with Citigroup repeating the rating for CLDX by listing it as a “Buy.” The predicted price for CLDX in the upcoming period, according to Citigroup is $70 based on the research report published on October 07, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see CLDX reach a price target of $45. The rating they have provided for CLDX stocks is “Neutral” according to the report published on September 30th, 2024.
CLDX Trading at -14.47% from the 50-Day Moving Average
After a stumble in the market that brought CLDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.36% of loss for the given period.
Volatility was left at 6.16%, however, over the last 30 days, the volatility rate increased by 7.56%, as shares sank -7.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.60% lower at present.
During the last 5 trading sessions, CLDX fell by -1.64%, which changed the moving average for the period of 200-days by -29.03% in comparison to the 20-day moving average, which settled at $26.16. In addition, Celldex Therapeutics Inc saw -33.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLDX starting from Marucci Anthony S, who purchase 11,500 shares at the price of $26.82 back on Nov 11 ’24. After this action, Marucci Anthony S now owns 40,284 shares of Celldex Therapeutics Inc, valued at $308,430 using the latest closing price.
Martin Samuel Bates, the SVP AND CFO of Celldex Therapeutics Inc, sale 17,172 shares at $35.42 during a trade that took place back on Jun 14 ’24, which means that Martin Samuel Bates is holding 28,125 shares at $608,315 based on the most recent closing price.
Stock Fundamentals for CLDX
Current profitability levels for the company are sitting at:
- -17.46 for the present operating margin
- 0.77 for the gross margin
The net margin for Celldex Therapeutics Inc stands at -15.44. The total capital return value is set at -0.22. Equity return is now at value -29.84, with -27.93 for asset returns.
Currently, EBITDA for the company is -139.03 million with net debt to EBITDA at 0.19. When we switch over and look at the enterprise to sales, we see a ratio of 172.23. The receivables turnover for the company is 11.71for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 24.27.
Conclusion
To wrap up, the performance of Celldex Therapeutics Inc (CLDX) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
